2026 Q1 -tulosraportti
50 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,80%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenEffective July 1 - major discount in the USA The US government is launching a new program, Medicare GLP-1 Bridge, which from July 1, 2026, to December 31, 2027, will give certain Medicare recipients access to weight-loss medication for only 50 USD per month. Which medications are covered? * Wegovy (injections and tablets) * Zepbound KwikPen * Foundayo Up to 14 million Americans could potentially be eligible. Who can get access? Individuals with: * BMI ≥ 35, or * BMI ≥ 30 with comorbidities such as heart failure, uncontrolled hypertension, or kidney disease, or * BMI ≥ 27 with risk factors such as prediabetes or peripheral artery disease. Why is this important? Previously, Medicare generally did not cover weight-loss medication. The program therefore opens the market for millions of patients who otherwise could not afford the treatment. Significance for Novo and Lilly Positive for both companies, especially: * Novo Nordisk via Wegovy * Eli Lilly and Company via Zepbound and Foundayo The program significantly lowers patient co-payments and can increase the number of patients on GLP-1 treatment. Limitations * The program is temporary and expires at the end of 2027. * The 50 USD does not count towards Medicare Part D’s deductible or out-of-pocket maximum. * Patients may risk losing the discount when the program ends. * Long-term treatment is often necessary to avoid weight regain after discontinuation. Investor Perspective For investors, the most important point is that the US government now actively supports access to obesity medication. This signals that the GLP-1 market is moving from a niche product to a broader part of the healthcare system. In the short term, this is likely: * Bullish for Novo Nordisk, as Wegovy is among the covered products. * Bullish for Eli Lilly, as both Zepbound and Foundayo are included. * Positive for the entire obesity medication sector, because more patients can afford treatment. If the program shows health benefits and reduces overall healthcare costs, it could strengthen the argument for more permanent Medicare coverage after 2027. This will be a much larger long-term catalyst than the pilot project itself.
·7 t sitten47,58 USD in after-hours trading in the USA tonight. That probably corresponds to 314,30 DK ????- ·8 t sittenHere is perhaps the reason why the Wegovy pill is preferred - probably the same we will see in Europe. Novo Nordisk's early success with the oral Wegovy tablet is largely due, according to the analysis firm Spherix Global Insights, to "familiarity" – i.e., recognition in the market – rather than just being first to market. Analyst Jim Hickey has interviewed doctors in the USA and points out that doctors are more comfortable with semaglutide, which is already known from the injectable Novo Nordisk treatment Wegovy Wegovy. The new tablet shares the active substance (semaglutide) with the existing treatment, which provides higher confidence and faster adoption. In comparison, competitor Eli Lilly has launched the oral drug "Foundayo" (orforglipron), which is a completely new molecule and therefore less known among doctors. This means that, according to the analysis, it is perceived as less "familiar" and more uncertain in practice.There is apparently a vast difference between what the analysts believe and what the doctors do.
·8 t sitten47,58 USD in after-hours trading in the USA tonight. That probably corresponds to 313,30 DKK?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
50 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,80%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenEffective July 1 - major discount in the USA The US government is launching a new program, Medicare GLP-1 Bridge, which from July 1, 2026, to December 31, 2027, will give certain Medicare recipients access to weight-loss medication for only 50 USD per month. Which medications are covered? * Wegovy (injections and tablets) * Zepbound KwikPen * Foundayo Up to 14 million Americans could potentially be eligible. Who can get access? Individuals with: * BMI ≥ 35, or * BMI ≥ 30 with comorbidities such as heart failure, uncontrolled hypertension, or kidney disease, or * BMI ≥ 27 with risk factors such as prediabetes or peripheral artery disease. Why is this important? Previously, Medicare generally did not cover weight-loss medication. The program therefore opens the market for millions of patients who otherwise could not afford the treatment. Significance for Novo and Lilly Positive for both companies, especially: * Novo Nordisk via Wegovy * Eli Lilly and Company via Zepbound and Foundayo The program significantly lowers patient co-payments and can increase the number of patients on GLP-1 treatment. Limitations * The program is temporary and expires at the end of 2027. * The 50 USD does not count towards Medicare Part D’s deductible or out-of-pocket maximum. * Patients may risk losing the discount when the program ends. * Long-term treatment is often necessary to avoid weight regain after discontinuation. Investor Perspective For investors, the most important point is that the US government now actively supports access to obesity medication. This signals that the GLP-1 market is moving from a niche product to a broader part of the healthcare system. In the short term, this is likely: * Bullish for Novo Nordisk, as Wegovy is among the covered products. * Bullish for Eli Lilly, as both Zepbound and Foundayo are included. * Positive for the entire obesity medication sector, because more patients can afford treatment. If the program shows health benefits and reduces overall healthcare costs, it could strengthen the argument for more permanent Medicare coverage after 2027. This will be a much larger long-term catalyst than the pilot project itself.
- ·7 t sitten47,58 USD in after-hours trading in the USA tonight. That probably corresponds to 314,30 DK ????
- ·8 t sittenHere is perhaps the reason why the Wegovy pill is preferred - probably the same we will see in Europe. Novo Nordisk's early success with the oral Wegovy tablet is largely due, according to the analysis firm Spherix Global Insights, to "familiarity" – i.e., recognition in the market – rather than just being first to market. Analyst Jim Hickey has interviewed doctors in the USA and points out that doctors are more comfortable with semaglutide, which is already known from the injectable Novo Nordisk treatment Wegovy Wegovy. The new tablet shares the active substance (semaglutide) with the existing treatment, which provides higher confidence and faster adoption. In comparison, competitor Eli Lilly has launched the oral drug "Foundayo" (orforglipron), which is a completely new molecule and therefore less known among doctors. This means that, according to the analysis, it is perceived as less "familiar" and more uncertain in practice.There is apparently a vast difference between what the analysts believe and what the doctors do.
- ·8 t sitten47,58 USD in after-hours trading in the USA tonight. That probably corresponds to 313,30 DKK?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
50 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,80%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenEffective July 1 - major discount in the USA The US government is launching a new program, Medicare GLP-1 Bridge, which from July 1, 2026, to December 31, 2027, will give certain Medicare recipients access to weight-loss medication for only 50 USD per month. Which medications are covered? * Wegovy (injections and tablets) * Zepbound KwikPen * Foundayo Up to 14 million Americans could potentially be eligible. Who can get access? Individuals with: * BMI ≥ 35, or * BMI ≥ 30 with comorbidities such as heart failure, uncontrolled hypertension, or kidney disease, or * BMI ≥ 27 with risk factors such as prediabetes or peripheral artery disease. Why is this important? Previously, Medicare generally did not cover weight-loss medication. The program therefore opens the market for millions of patients who otherwise could not afford the treatment. Significance for Novo and Lilly Positive for both companies, especially: * Novo Nordisk via Wegovy * Eli Lilly and Company via Zepbound and Foundayo The program significantly lowers patient co-payments and can increase the number of patients on GLP-1 treatment. Limitations * The program is temporary and expires at the end of 2027. * The 50 USD does not count towards Medicare Part D’s deductible or out-of-pocket maximum. * Patients may risk losing the discount when the program ends. * Long-term treatment is often necessary to avoid weight regain after discontinuation. Investor Perspective For investors, the most important point is that the US government now actively supports access to obesity medication. This signals that the GLP-1 market is moving from a niche product to a broader part of the healthcare system. In the short term, this is likely: * Bullish for Novo Nordisk, as Wegovy is among the covered products. * Bullish for Eli Lilly, as both Zepbound and Foundayo are included. * Positive for the entire obesity medication sector, because more patients can afford treatment. If the program shows health benefits and reduces overall healthcare costs, it could strengthen the argument for more permanent Medicare coverage after 2027. This will be a much larger long-term catalyst than the pilot project itself.
- ·7 t sitten47,58 USD in after-hours trading in the USA tonight. That probably corresponds to 314,30 DK ????
- ·8 t sittenHere is perhaps the reason why the Wegovy pill is preferred - probably the same we will see in Europe. Novo Nordisk's early success with the oral Wegovy tablet is largely due, according to the analysis firm Spherix Global Insights, to "familiarity" – i.e., recognition in the market – rather than just being first to market. Analyst Jim Hickey has interviewed doctors in the USA and points out that doctors are more comfortable with semaglutide, which is already known from the injectable Novo Nordisk treatment Wegovy Wegovy. The new tablet shares the active substance (semaglutide) with the existing treatment, which provides higher confidence and faster adoption. In comparison, competitor Eli Lilly has launched the oral drug "Foundayo" (orforglipron), which is a completely new molecule and therefore less known among doctors. This means that, according to the analysis, it is perceived as less "familiar" and more uncertain in practice.There is apparently a vast difference between what the analysts believe and what the doctors do.
- ·8 t sitten47,58 USD in after-hours trading in the USA tonight. That probably corresponds to 313,30 DKK?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt